Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
Go back to Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer| (NASDAQ: NTRA) | Delayed: 324.35 -3.83 (1.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $328.18 | 52 Week High | $13.80 | |||
| Open | $326.29 | 52 Week Low | $6.52 | |||
| Day High | $328.54 | P/E | N/A | |||
| Day Low | $321.21 | EPS | $0.00 | |||
| Volume | 160,171 | |||||

